Drug – bio-affecting and body treating compositions – Topical sun or radiation screening – or tanning preparations
Reexamination Certificate
2001-12-14
2003-04-29
Dodson, Shelley A (Department: 1616)
Drug, bio-affecting and body treating compositions
Topical sun or radiation screening, or tanning preparations
C424S060000, C424S400000, C424S401000
Reexamination Certificate
active
06555095
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to topical compositions. More particularly, the present invention relates to compositions having a cosmetic, drug or medicinal active and a compound (hereinafter “novel compound”) having an aromatic moiety, a lipophilic moiety, and a hydrophilic moiety in which the novel compound has emulsifying and/or photostabilizing properties.
2. Description of the Prior Art
Many cosmetic compositions are susceptible to photodegradation. Prior art methods of addressing such concerns have included packaging such compositions in special containers, such as containers formed from light-impervious materials. However, these types of containers are not always preferred in the consumer product industry where packaging can determine the success of the product. It would be desirable to have compositions, especially cosmetic and personal care compositions, that have improved photostability.
In addition, emulsions have one or more emulsifiers to maintain and stabilize phase separation and dispersion of the internal phase within the external phase. Emulsifiers also help prevent precipitation and/or crystallization of components, including sunscreen actives. Emulsifiers also improve the overall aesthetic appearance of the emulsions.
It would be desirable to have emulsions that provide a greater degree of phase separation and stability, reduced incidence of precipitation and/or crystallization of components, and improved overall aesthetic appearance. It is also desirable to formulate a product using the least amount of emulsifier possible, in order to maintain as low a cost as possible for the finished formulation. Furthermore, it is desirable to improve the photostability of topical compositions.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a topical composition that has improved photostability.
It is also an object of the present invention to provide an emulsion composition that provides a high degree of stability and a low incidence of phase separation, precipitation and/or crystallization of emulsion components.
It is also an object of the present invention to provide a composition that is suitable for topical application and is cosmetically elegant and has a pleasing aesthetic appearance.
It is another object of the present invention to improve the photostability of a topical composition having a cosmetic, drug or medicinal active, particularly one containing one or more sunscreen actives.
It is yet another object of the present invention to provide a novel compound that, when used in conjunction with a sunscreen, enhances the sunscreen protection factor (“SPF”) provided by the composition.
These and other objects and advantages of the present invention are achieved by utilizing the topical compositions of the present invention. The compositions have a cosmetic, drug or medicinal active, preferably having an aromatic moiety, the novel compound of the present invention, and a vehicle. The novel compound in the compositions has a formula selected from the group consisting of L—A—H (Formula I) and A—L—H (Formula II), wherein L is a lipophilic moiety, A is an aromatic moiety having an ultraviolet absorption maximum between 290 and 400 nanometers, preferably when measured in ethanol, and H is a hydrophilic moiety.
It is another object of the present invention to provide a solubilizer to improve the solubility of a cosmetic or medicinal active in a topical composition.
It is another object of the present invention to improve the photostability of a composition, particularly one having a sunscreen active, by adding to it the novel compound.
It is another object of the present invention to improve the effectiveness of a sunscreen composition by adding to it the novel compound.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to topical compositions having improved photostability and decreased photodegradation. The compositions may be emulsions, especially aqueous emulsions, and exhibit a high degree of stability and a low incidence of phase separation, precipitation and/or crystallization of ingredients. The compositions also have an excellent overall aesthetic appearance.
The novel compounds have a formula that is selected from the group consisting of L—A—H (Formula I) and A—L—H (Formula II) wherein A is an aromatic moiety, L is a lipophilic moiety, and H is a hydrophilic moiety. Novel compounds of the formula L—A—H are preferred. It is within the scope of the present invention that the novel compounds may have additional moieties, but the novel compounds must have at least the above three moieties (i.e., L, A and H) in either sequence indicated. Additional moieties may be attached to either end or between the moieties. Although Formula I novel compounds are preferred where ease of synthesis and cost are of concern, Formula II novel compounds are believed to better achieve the benefits of the present invention.
The lipophilic moiety may be a chain, preferably linear, having 2 to 24 carbon atoms. The chain may be branched or unbranched and saturated or unsaturated. The lipophilic moiety may also be a nonionic polyoxyalkylene chain of the formula (CxHyO)n, where x is 3 or more, n is 2 or more, and y is from 2x−2 to 2x. The lipophilic moiety of the novel compound has an affinity for the oil phase of the emulsion.
Examples of suitable lipophilic moieties include branched or unbranched alkyl groups having from about 4 to about 24 carbon atoms, and preferably from about 8 to about 18 carbon atoms. Other examples include polyoxypropylene chains having a range of propoxylation, i.e. number of propylene oxide (PO) units, from 2 to about 160, preferably from about 5 to about 40 and most preferably from about 10 to about 20. As is known by those skilled in the art, the degree of propoxylation may be adjusted to provide desired properties.
The aromatic moiety has at least one benzene ring, which may be functionalized or nonfunctionalized. The aromatic moiety has an intrinsic ultraviolet absorption maximum between 290 and 400 nanometers that imparts to the novel compound an absorptivity value of about 5 or more. The absorptivity value is measured as defined in US Pharmacopiea 25, which is incorporated herein by reference, especially page 2075 thereof. It is known and understood in the art that a compound may have more than one UV maximum, since the maximum absorbance peaks are due to electronic transitions, and often more than one such transition is observed. The aromatic moiety may have para, meta, or ortho substitution. Para substitution is most preferred followed by meta substitution. In addition, when the novel compound is the structure represented in Formula I, it is preferred that the lipophilic and hydrophilic moieties are in the para positions. The aromatic moiety and the lipophilic moiety of the novel compound are different. The lipophilic moiety preferably does not have an aromatic group therein.
Examples of suitable aromatic moieties useful in the present invention include, but are not limited to, one or more salicylates, anthranilates, cinnamates, methoxycinnamates, ferulates, para amino benzoates, dibenzoyl methanes, benzophenones, phenyl benzamidazoles, cyano diphenyl acrylates, benzylidenes, hydroxy benzylidenes, biphenyls, terephthalylidenes, triazines, naphthalene dicarboxylates, digallic acids, gallic acids, gallates, triazones, or any combinations thereof. Preferred aromatic moieties are cinnamates, benzophenones, dibenzoyl methanes, and salicylates. A preferred dibenzoyl methane moiety is butylmethoxydibenzoyl methane. By way of example, the methoxycinnamate moiety is depicted in Formula Y below:
It is preferred that when the novel compound is Formula I and the aromatic moiety is benzylidene, the lipophilic moiety is not camphor.
Examples of hydrophilic moieties include nonionic groups such as polyoxyethylene chains having at least 2 ethylene oxide (EO) units, anionic groups such carboxylates, phosphates, sulfates, sulfonates, and cationic groups such as qua
Avon Products Inc.
Dodson Shelley A
Ohlandt Greeley Ruggiero & Perle LLP
LandOfFree
Topical compositions and methods of application does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical compositions and methods of application, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical compositions and methods of application will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3080773